Clinical Trial Update: Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial evaluating a multi-modular CAR-T therapy targeting GD2 for neuroblastoma. The study is active but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• GD2-targeted multi-modular CAR-T

Snippet

Sponsor: University College, London | Conditions: Neuroblastoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING